JP2024522312A5 - - Google Patents
Info
- Publication number
- JP2024522312A5 JP2024522312A5 JP2023566547A JP2023566547A JP2024522312A5 JP 2024522312 A5 JP2024522312 A5 JP 2024522312A5 JP 2023566547 A JP2023566547 A JP 2023566547A JP 2023566547 A JP2023566547 A JP 2023566547A JP 2024522312 A5 JP2024522312 A5 JP 2024522312A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- atoms
- group
- linear
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110475315 | 2021-04-29 | ||
| CN202110475315.1 | 2021-04-29 | ||
| PCT/CN2022/089724 WO2022228493A1 (zh) | 2021-04-29 | 2022-04-28 | 抗体偶联药物的制备方法及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522312A JP2024522312A (ja) | 2024-06-14 |
| JP2024522312A5 true JP2024522312A5 (cg-RX-API-DMAC10.html) | 2025-04-02 |
Family
ID=83846703
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566660A Pending JP2024522389A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
| JP2023566547A Pending JP2024522312A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
| JP2023566659A Active JP7900834B2 (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566660A Pending JP2024522389A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566659A Active JP7900834B2 (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20240238440A1 (cg-RX-API-DMAC10.html) |
| EP (3) | EP4331612A4 (cg-RX-API-DMAC10.html) |
| JP (3) | JP2024522389A (cg-RX-API-DMAC10.html) |
| KR (2) | KR20240006029A (cg-RX-API-DMAC10.html) |
| CN (3) | CN117241834A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022263700A1 (cg-RX-API-DMAC10.html) |
| CA (3) | CA3173758A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL308025A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202308701A (cg-RX-API-DMAC10.html) |
| WO (3) | WO2022228495A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240238440A1 (en) * | 2021-04-29 | 2024-07-18 | Hyslink Therapeutics | Preparation method for and application of antibody conjugated drug |
| CA3266848A1 (en) | 2022-10-19 | 2024-04-25 | Multitude Therapeutics Inc. | Antibodies, antibody-drug conjugates, preparations and uses thereof |
| KR20250079227A (ko) * | 2022-10-25 | 2025-06-04 | 머크 샤프 앤드 돔 엘엘씨 | 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도 |
| JP2026504840A (ja) * | 2023-01-11 | 2026-02-10 | ジェンマブ エー/エス | リンカー、薬物リンカー、およびそれらの複合体、ならびにそれらを使用する方法 |
| CN122080121A (zh) * | 2023-03-22 | 2026-05-26 | 映恩生物科技(上海)有限公司 | 连接子及其在配体药物偶联物中的应用 |
| TW202438069A (zh) * | 2023-03-30 | 2024-10-01 | 大陸商上海齊魯製藥研究中心有限公司 | 依喜替康衍生物及其抗體藥物偶聯物 |
| WO2024212922A1 (zh) * | 2023-04-11 | 2024-10-17 | 映恩生物制药(苏州)有限公司 | 喜树碱类化合物及其偶联物、其制备方法和用途 |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| CN119300868B (zh) * | 2023-05-11 | 2026-03-13 | 映恩生物科技(上海)有限公司 | 喜树碱类化合物及其偶联物、其制备方法和用途 |
| EP4713020A2 (en) * | 2023-05-19 | 2026-03-25 | Solve Therapeutics, Inc. | Drug-linkers and drug conjugates |
| WO2024250984A1 (zh) * | 2023-06-07 | 2024-12-12 | 上海维申医药有限公司 | 一种抗体药物偶联物,及其药物组合物、制备和用途 |
| EP4737483A1 (en) * | 2023-06-30 | 2026-05-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate production method including purification step using activated carbon material |
| WO2025011419A1 (zh) | 2023-07-07 | 2025-01-16 | 上海诗健生物科技有限公司 | 一种连接子-药物分子及抗体药物偶联物、其制备方法和应用 |
| IL326233A (en) * | 2023-08-04 | 2026-03-01 | Shanghai Huao Co Ltd | Multidrug Linker and Antibody-Drug Conjugation |
| IL324001A (en) * | 2023-09-22 | 2025-12-01 | Obi Pharma Inc | Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof |
| AU2024369355A1 (en) | 2023-10-23 | 2026-05-07 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Camptothecin drug conjugate, and preparation method therefor and use thereof |
| EP4566631A1 (en) * | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| WO2025149019A1 (en) * | 2024-01-12 | 2025-07-17 | Shanghai Ruotuo Biosciences Co., Ltd. | Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications |
| WO2025153092A1 (en) * | 2024-01-18 | 2025-07-24 | Beijing Joinn Biologics Co., Ltd | Antibody-drug conjugate |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025209545A1 (zh) * | 2024-04-03 | 2025-10-09 | 上海药明合联生物技术有限公司 | 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物 |
| WO2025222052A2 (en) * | 2024-04-18 | 2025-10-23 | Solve Therapeutics, Inc. | Conjugates and uses thereof |
| WO2025259928A1 (en) * | 2024-06-13 | 2025-12-18 | Obi Pharma, Inc. | Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof |
| WO2025261478A1 (en) * | 2024-06-21 | 2025-12-26 | Biotheus Inc. | Antibody drug conjugates and applications thereof |
| WO2026039642A1 (en) | 2024-08-16 | 2026-02-19 | Ardeagen Corporation | Anti-mesothelin antibody conjugates and methods of use thereof |
| WO2026037394A1 (zh) * | 2024-08-16 | 2026-02-19 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物及其用途 |
| WO2026046186A1 (en) * | 2024-08-27 | 2026-03-05 | Suzhou Bioreinno Biotechnology Limited Company | Linkers, linker conjugates and conjugate compounds thereof |
| WO2026067624A1 (zh) * | 2024-09-27 | 2026-04-02 | 上海森辉医药有限公司 | 一种包含亲水基团的配体-药物偶联物及其在医药上的应用 |
| CN119143876B (zh) * | 2024-10-09 | 2025-09-16 | 武汉海沙百得生物技术有限公司 | 一种抗cd27l的全人源抗体或抗体片段及其应用 |
| WO2026078443A1 (en) | 2024-10-11 | 2026-04-16 | Pheon Therapeutics Ltd. | Antibody drug conjugates that bind cdcp1 and uses thereof |
| CN120484249B (zh) * | 2025-04-29 | 2026-03-10 | 中山大学 | 一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391745A (en) * | 1992-07-23 | 1995-02-21 | Sloan-Kettering Institute For Cancer Research | Methods of preparation of camptothecin analogs |
| AU2002363658B2 (en) * | 2001-11-14 | 2008-09-11 | Rutgers, The State University | Solubilized topoisomerase poisons |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| KR20210132742A (ko) * | 2012-12-21 | 2021-11-04 | 알트루바이오 인코퍼레이티드 | 친수성 자기-희생 링커 및 그것의 포합체 |
| MY173295A (en) | 2013-04-16 | 2020-01-14 | Genentech Inc | Pertuzumab variants and evaluation thereof |
| GB2529356B (en) * | 2013-04-28 | 2020-12-23 | Genequantum Healthcare Co Ltd | Novel linkers, coupling intermediates, conjugates, preparation method and application thereof |
| SG10201902571VA (en) * | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| EP3517114A1 (en) * | 2014-04-29 | 2019-07-31 | Genequantum Healthcare (Suzhou) Co., Ltd. | New stable antibody-drug conjugate, preparation method and use thereof |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| EP3347048B1 (en) | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| CN108066772B (zh) * | 2016-11-14 | 2021-07-13 | 中国科学院上海药物研究所 | 靶向tacstd2的抗体与药物偶联体(adc)分子 |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| EP3700577A1 (en) | 2017-10-23 | 2020-09-02 | Mablink Bioscience | Ligand-drug-conjugate comprising a single molecular weight polysarcosine |
| EP3790590A1 (en) | 2018-05-10 | 2021-03-17 | CIS Pharma AG | Biocompatible copolymer containing multiple active agent molecules |
| CA3140063A1 (en) * | 2019-05-20 | 2020-11-26 | Novartis Ag | Antibody drug conjugates having linkers comprising hydrophilic groups |
| CA3085001C (en) | 2019-05-20 | 2021-10-05 | Mabplex International, Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
| US20240238440A1 (en) * | 2021-04-29 | 2024-07-18 | Hyslink Therapeutics | Preparation method for and application of antibody conjugated drug |
| AU2022406708A1 (en) * | 2021-12-10 | 2024-06-27 | Multitude Therapeutics Inc. | Anti-cdh6 antibodies and antibody-drug conjugates thereof |
| CA3266848A1 (en) * | 2022-10-19 | 2024-04-25 | Multitude Therapeutics Inc. | Antibodies, antibody-drug conjugates, preparations and uses thereof |
-
2022
- 2022-04-28 US US18/557,448 patent/US20240238440A1/en active Pending
- 2022-04-28 US US18/557,454 patent/US20240245799A1/en active Pending
- 2022-04-28 AU AU2022263700A patent/AU2022263700A1/en active Pending
- 2022-04-28 TW TW111116237A patent/TW202308701A/zh unknown
- 2022-04-28 WO PCT/CN2022/089726 patent/WO2022228495A1/zh not_active Ceased
- 2022-04-28 CA CA3173758A patent/CA3173758A1/en active Pending
- 2022-04-28 CA CA3173902A patent/CA3173902A1/en active Pending
- 2022-04-28 WO PCT/CN2022/089725 patent/WO2022228494A1/zh not_active Ceased
- 2022-04-28 JP JP2023566660A patent/JP2024522389A/ja active Pending
- 2022-04-28 CA CA3173511A patent/CA3173511A1/en active Pending
- 2022-04-28 EP EP22794964.1A patent/EP4331612A4/en active Pending
- 2022-04-28 KR KR1020237041142A patent/KR20240006029A/ko active Pending
- 2022-04-28 IL IL308025A patent/IL308025A/en unknown
- 2022-04-28 US US18/557,445 patent/US20240245795A1/en active Pending
- 2022-04-28 CN CN202280030774.1A patent/CN117241834A/zh active Pending
- 2022-04-28 JP JP2023566547A patent/JP2024522312A/ja active Pending
- 2022-04-28 WO PCT/CN2022/089724 patent/WO2022228493A1/zh not_active Ceased
- 2022-04-28 CN CN202280030770.3A patent/CN117241833A/zh active Pending
- 2022-04-28 EP EP22794963.3A patent/EP4331611A4/en active Pending
- 2022-04-28 CN CN202280030781.1A patent/CN117337195A/zh active Pending
- 2022-04-28 EP EP22794965.8A patent/EP4331613A4/en active Pending
- 2022-04-28 KR KR1020237041141A patent/KR20240006028A/ko active Pending
- 2022-04-28 JP JP2023566659A patent/JP7900834B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024522388A5 (cg-RX-API-DMAC10.html) | ||
| JP2024522389A5 (cg-RX-API-DMAC10.html) | ||
| CN103483236B (zh) | 制备5-联苯-4-基-2-甲基戊酸衍生物的方法和中间体 | |
| AU603999B2 (en) | Porphyrin derivatives, and their production and use | |
| CN103080072B (zh) | 制备可用于生产nep抑制剂的中间体的新方法 | |
| US5262532A (en) | Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging | |
| US6111107A (en) | High yield method for stereoselective acylation of tertiary alcohols | |
| JP2021138761A5 (cg-RX-API-DMAC10.html) | ||
| RU98110565A (ru) | Новые соединения и их композиции, обладающие противовоспалительной и противотромботической активностями | |
| JP2018511628A5 (cg-RX-API-DMAC10.html) | ||
| JP2021533181A5 (cg-RX-API-DMAC10.html) | ||
| US20150217005A1 (en) | Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of alzheimer's disease | |
| RU2012149448A (ru) | Новые конъюгаты аналогов сс-1065 и бифункциональные линкеры | |
| JP2016516063A5 (cg-RX-API-DMAC10.html) | ||
| JP2015501292A5 (cg-RX-API-DMAC10.html) | ||
| JP2009523841A5 (cg-RX-API-DMAC10.html) | ||
| RU2015125006A (ru) | Новые аналоги сс-1065 и их конъюгаты | |
| JP2005539009A5 (cg-RX-API-DMAC10.html) | ||
| JP2018516243A5 (cg-RX-API-DMAC10.html) | ||
| JP2005533026A5 (cg-RX-API-DMAC10.html) | ||
| JP2020534336A5 (cg-RX-API-DMAC10.html) | ||
| RU2007121697A (ru) | Гидроксибензоатные соли метаникотиновых соединений | |
| GB2614981A (en) | Therapeutic cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and using them | |
| RU2005135139A (ru) | Медиаторы обратного трансорта холестерина для лечения гиперхолестеринемии | |
| JP2021527064A5 (cg-RX-API-DMAC10.html) |